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Abstract 
Based on clinical and animal studies, this review suggests a tri-phasic effect of second-generation 
antipsychotics (SGAs) on circulating ghrelin levels: an initial increase exerted by the acute effect of SGAs; 
followed by a secondary decrease possibly due to the negative feedback from the SGA-induced body 
weight gain or hyperphagia; and a final re-increase to reach the new equilibrium. Moreover, the results can 
also vary depending on individual SGAs, other hormonal states, dietary choices, and other confounding 
factors including medical history, co-treatments, age, gender, and ghrelin measurement techniques. 
Interestingly, rats treated with olanzapine, an SGA with high weight gain liabilities, are associated with 
increased hypothalamic ghrelin receptor (GHS-R1a) levels. In addition, expressions of downstream ghrelin 
signalling parameters at the hypothalamus, including neuropeptide Y (NPY)/agouti-related peptide (AgRP) 
and proopiomelanocortin (POMC) are also altered under SGA treatments. Thus, understanding the role of 
ghrelin signalling in antipsychotic drug-induced weight gain should offer potential novel pharmacological 
targets for tackling the obesity side-effect of SGAs and its associated metabolic syndrome. 
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Based on clinical and animal studies, this review suggests a tri-phasic effect of second-generation 
antipsychotics (SGAs) on circulating ghrelin levels: an initial increase exerted by the acute effect of 
SGAs; followed by a secondary decrease possibly due to the negative feedback from the SGA-
induced body weight gain or hyperphagia; and a final re-increase to reach the new equilibrium. 
Moreover, the results can also vary depending on individual SGAs, other hormonal states, dietary 
choices, and other confounding factors including medical history, co-treatments, age, gender, and 
ghrelin measurement techniques. Interestingly, rats treated with olanzapine, an SGA with high 
weight gain liabilities, are associated with increased hypothalamic ghrelin receptor (GHS-R1a) 
levels. In addition, expressions of downstream ghrelin signalling parameters at the hypothalamus, 
including neuropeptide Y (NPY)/ agouti-related peptide (AgRP) and proopiomelanocortin (POMC) 
are also altered under SGA treatments. Thus, understanding the role of ghrelin signalling in 
antipsychotic drug-induced weight gain should offer potential novel pharmacological targets for 
tackling the obesity side-effect of SGAs and its associated metabolic syndrome. 
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Schizophrenia is a complex mental disorder affecting approximately 1.5% of the adult population 
worldwide (Bhugra, 2005). Second-generation antipsychotics (SGAs) have become the primary 
treatment for schizophrenia and other psychotic disorders due to their claimed superior efficacy and 
induction of fewer extrapyramidal side-effects compared to the first-generation antipsychotics 
(Kane et al., 2009; Leucht et al., 2009a; Leucht et al., 2009b). However, metabolic side-effects, in 
particular body weight gain, have emerged as an increasing concern for SGAs in light of their 
accompanying complications and deterioration in drug compliance (Lieberman et al., 2005). 
Although some valuable insights have been achieved, the mechanism of SGA-induced weight gain 
remains unclear. 
Ghrelin is a 28-amino-acid orexigenic hormone secreted mainly from the X/A-like cells (rodent 
equivalent of the human P/D1 cells) at the fundus of the stomach (Kojima et al., 1999; Nakazato et 
al., 2001; Tschop et al., 2000). Ghrelin could increase food intake and lead to body weight gain in 
humans (Adachi et al., 2010; Druce et al., 2005), which coincides with clinical observations that 
patients on antipsychotics often experience increased appetite and food intake. In addition, clinical 
(Basoglu et al., 2010; Chen et al., 2011; Esen-Danaci et al., 2008; Hosojima et al., 2006; Kim et al., 
2008; Murashita et al., 2007a; Murashita et al., 2005; Palik et al., 2005; Perez-Iglesias et al., 2008; 
Roerig et al., 2008; Tanaka et al., 2008; Togo et al., 2004; Vidarsdottir et al., 2010) and animal 
studies (Albaugh et al., 2006; Davey et al., 2012; Weston-Green et al., 2011) suggest that SGA 
treatments modulate circulating ghrelin levels. Moreover, rats treated with olanzapine, an SGA with 
significant weight gain liabilities, have elevated hypothalamic ghrelin receptor (also called growth 
hormone secretagogue receptor 1a; GHS-R1a) expression (Davey et al., 2012; Zhang et al., 2012), 
indicating that ghrelin signalling may play a role in antipsychotic-induced obesity.  
Multiple factors, such as the antagonism of the histaminergic H1 receptor and serotoninergic 5-
HT2c receptors have been suggested as important factors contributing to the weight gain side-effect 
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induced by SGAs (Kroeze et al., 2003; Nasrallah, 2008; Reynolds and Kirk, 2008); and the role of 
α-adrenergic (Nasrallah, 2008), muscarinic M3 (Weston-Green et al., 2012b), and histaminergic H3 
(Deng et al., 2010) antagonism has also been suggested. However, we have very limited 
understanding of the role of ghrelin signalling in SGA-induced body weight gain. Considering the 
fact that ghrelin is an important orexigenic circulating hormone, as well as the presence of GHS-
R1a and ghrelin at the hypothalamic arcuate nucleus (Arc), the energy homeostasis regulatory 
centre, elucidating the molecular mechanisms of ghrelin signalling under SGA treatments may 
assist in exploring pharmacological targets for tackling the weight gain side-effects of SGAs. 
2. The ghrelin signalling system 
2.1 Ghrelin and the ghrelin receptor 
The biochemical features and orexigenic actions of ghrelin and the ghrelin receptor have been 
reviewed previously (Andrews, 2011a; Castaneda et al., 2010; Schellekens et al., 2010). Ghrelin is 
posttranslationally acylated by the enzyme ghrelin O-acyltransferase (GOAT) on Ser3 of the ghrelin 
peptide, which is essential for binding ghrelin to the GHS-R1a receptor (Andrews, 2011b; Bednarek 
et al., 2000; Schellekens et al., 2010; Yang et al., 2008). The GHS-R1a receptor is highly expressed 
in the Arc, where food intake and energy homeostasis are regulated (Harrold et al., 2008).  
Recent findings of the heterodimerization between the GHS-R1a receptor and other G protein-
coupled receptors, including the dopaminergic D1 and D2, the serotoninergic 5-HT2c, and the 
melanocortinergic MC4 receptors (Jiang et al., 2006; Kern et al., 2012; Rediger et al., 2011; 
Schellekens et al., 2013), have shed light on novel mechanisms of food intake and body weight 
regulation via the ghrelinergic system. Further, SGAs such as olanzapine and clozapine are 
antagonists of the D2 and 5-HT2c receptors, which induces weight gain (Nasrallah, 2008). Hence 
the weight gain liabilities of these SGAs can also be due to the functional interactions between these 
receptors and the GHS-R1a receptor.  
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2.2 Transduction of ghrelin signals from the peripheral to the brain 
Several lines of evidence support the role of the vagus-nucleus of the solitary tract (NTS)-Arc 
pathway in ghrelin signal transduction from the peripheral to the brain (Fig.1a). Blockade of the 
gastric vagal afferent pathways by either vagotomy or capsaicin application abolished peripheral 
ghrelin-induced feeding in rats (Chen et al., 2005; Date et al., 2002), mice (Asakawa et al., 2001), 
and humans (le Roux et al., 2005), although contradictory results exist in rats (Arnold et al., 2006). 
Further, the GHS-R1a receptor is also expressed in the nodose ganglion of the stomach-projected 
vagal afferent neurons (Sakata et al., 2003), which synapse centrally at the NTS. The NTS is the 
termination area of the vagal afferents which receive viscerosensory information from the 
gastrointestinal tract, and contains the A2 noradrenergic neurons which project to numerous 
hypothalamic nuclei including the Arc (Sawchenko and Swanson, 1981).   
Direct action of ghrelin on the hypothalamic Arc through the blood-brain barrier (BBB) is also 
possible (Fig.1a), since saturable transport of acylated ghrelin across the BBB has been evidenced 
(Banks et al., 2002; Pan et al., 2006). An alternative pathway could be the binding of ghrelin to the 
GHS-R1a receptor at the dorsal vagal complex (DVC) of the brainstem, in particular the area 
postrema (AP) where the BBB is incomplete, and projects to the hypothalamus (Fig.1a). Selective 
ablation of the AP blocks pancreatic secretion triggered by intravenous infusion of ghrelin, which 
was substantiated by the elimination of the ghrelin-induced c-fos expression at the AP, NTS and 
dorsal motor nucleus of the vagus (DMV) (Li et al., 2006).  Finally, a small amount of ghrelin is 
produced in the hypothalamus, since ghrelin-containing neurons have been detected in the Arc (Lu 
et al., 2001) as well as in an area adjacent to the third ventricle and between the Arc, the 
dorsomedial hypothalamus (DMH), the ventromedial hypothalamus (VMH) and the paraventricular 
nucleus (PVN) (Cowley et al., 2003). 
2.3 Central ghrelin signalling and food intake 
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The involvement of ghrelin signalling adds a new dimension to the hypothalamic network of energy 
balance regulation (Fig.1b). At the Arc, ghrelin can upregulate NPY and AgRP and downregulate 
POMC expressions, contributing to the orexigenic effect of ghrelin. Interestingly, the SGA 
olanzapine has been reported to upregulate NPY and AgRP, and downregulate POMC at the 
hypothalamic Arc (Fernø et al., 2011; Weston-Green et al., 2012a), suggesting that ghrelin 
signalling can be involved in the SGA-induced elevation of food intake. 
The regulation of NPY and AgRP expressions in the Arc NPY/AgRP neurons by ghrelin via the 
AMP-activated protein kinase (AMPK) signalling is reviewed by Andrews (Andrews, 2011a). 
Briefly, activation of the GHS-R1a receptor at the level of Arc NPY/AgRP cells promotes 
mitochondria β-oxidation, tentatively through the AMPK – carnitine palmitoyltransferase 1 (CPT1) 
– uncoupling protein 2 (UCP2) pathways. Central inhibition of AMPK signalling reduced the 
orexigenic effect of ghrelin (López et al., 2008), and blocked the ghrelin-induced fatty acid synthase 
downregulation. Further, fasting-induced elevation of hypothalamic AMPK is associated with 
decreased malonyl-CoA and increased CPT1 activity (López et al., 2008). Finally, the postprandial 
suppression of AMPK was eliminated in UCP2 knockout but not in wild type mice (Andrews et al., 
2008). More recent studies have also indicated the roles of Sirtuin 1 (SIRT1)/p53 (Velasquez et al., 
2011) and CPT1c/ceramide (Ramirez et al., 2013) in the orexigenic effect of ghrelin signalling. 
Moreover, the mammalian target of rapamycin (mTOR) signalling pathway has also been suggested 
as an alternative pathway which mediates the orexigenic actions of ghrelin (Martins et al., 2012). 
The role of intracellular transcriptional factors in ghrelin-induced alterations of hypothalamic 
neuropeptides (Fig.2) has been highlighted recently (Lage et al., 2010). The forkhead box O1 
(FOXO1) and the phosphorylated cAMP-response element-binding protein (pCREB) have been 
demonstrated as transcriptional factors for the expression of AgRP and NPY, respectively (Kim et 
al., 2006; Kitamura et al., 2006; Sakkou et al., 2007; Shimizu-Albergine et al., 2001). FOXO1 is 
translocated into the nucleus of AgRP neurons, where it stimulates AgRP promoter activity (Kim et 
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al., 2006; Kitamura et al., 2006). Additionally, FOXO1 also stimulates NPY transcription by 
binding to the NPY promoters (Kim et al., 2006), and inhibits POMC promoter activity (Kim et al., 
2006; Kitamura et al., 2006), possibly by opposing the effect of signal transducer–activated 
transcript-3 (STAT3) (Kim et al., 2006). Recently FOXO1 knock-in mice with specific activation at 
the hypothalamus and pancreas have been reported to develop obesity and hyperphagia, with 
increased hypothalamic AgRP and NPY levels (Kim et al., 2012). It is suggested that the brain-
specific homeobox transcription factor (BSX) regulates both AgRP and NPY expression directly, 
and interacts with FOXO1 and pCREB, producing synergistic effects on the expression of AgRP 
and NPY, respectively (Sakkou et al., 2007). Interestingly, central administration of ghrelin 
increased the mRNA expression of BSX in the Arc and the protein expression of FOXO1 and 
pCREB in the hypothalamus in rodents (Lage et al., 2010; Nogueiras et al., 2008).  
3. Effects of SGAs on the ghrelin signalling system 
Previous reports have suggested controversial results of the effect of SGAs on circulating ghrelin 
levels (Sentissi et al., 2008; Jin et al., 2008). One earlier review paper suggested a bi-phasic effect, 
with downregulated and upregulated ghrelin levels under short- and long-term SGA treatments, 
respectively (Sentissi et al., 2008). Another review paper has proposed preliminary explanation 
suggesting that the negative feedback effect of ghrelin secretion is disrupted under SGA treatments 
in the long-term (Jin et al., 2008). Nevertheless, as more studies are added to the pool of knowledge 
on ghrelin levels under SGA treatments, these views are challenged and a re-evaluation is required. 
SGAs produced seemingly controversial effects on circulating ghrelin levels in both humans (Table 
1) and animals (Table 2). However, a detailed analysis on these studies according to the length of 
treatment reveals a tri-phasic effect of SGAs on ghrelin levels: an initial upregulatory effect; a 
downregulatory negative feedback effect in the short- to mid-term; and a final increase effect in the 
long-term (Fig. 3).  
3.1 Initial effects of SGAs on circulating ghrelin production 
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No clinical studies have reported on the acute effect of SGAs on circulating ghrelin levels, which 
makes the judgement of the initial effect of SGAs over ghrelin production difficult. However, one 
short-term study suggested that eight days of olanzapine treatment can lead to small but significant 
increase in pre- and postprandial total ghrelin levels (Vidarsdottir et al., 2010), indicating an acute 
upregulatory effect of SGAs on ghrelin production. This view is supported by two pharmacological 
animal studies which showed that acute olanzapine or clozapine treatments can increase both pre- 
and postprandial total ghrelin levels in rodents (van der Zwaal et al., 2012). Furthermore, our 
preliminary data also showed that one week of oral olanzapine treatment can increase plasma total 
ghrelin levels in rats (Zhang et al., unpublished data). Therefore, an initial upregulatory effect of 
SGAs on circulating ghrelin production is proposed. 
Neuronal control of ghrelin secretion includes vagal (parasympathetic) and sympathetic pathways 
(Fig. 4). The preprandial elevation and postprandial suppression of circulating ghrelin levels are 
both exaggerated by vagal stimulation (Heath et al., 2004). An inhibitory tone of vagus nerve over 
ghrelin production has been suggested (Lee et al., 2002; Toshinai et al., 2001; Weston-Green et al., 
2012b), which was supported by a truncal vagotomy study showing that plasma ghrelin was 
increased by vagotomy in rats (Lee et al., 2002), and ghrelin secretion is increased during fasting 
when vagal (parasympathetic) activity is low. Since olanzapine and clozapine, the two SGAs with 
highest risk of weight gain, are both muscarinic M1 and M3 antagonists (Nasrallah, 2008), it is 
conceivable that the blockage of vagal (parasympathetic) signalling pathways by these SGAs 
promotes ghrelin production (Weston-Green et al., 2012b). However, this view is in contrary to the 
findings of another subdiaphragmatic vagotomy study which showed that fasting-induced elevation 
of ghrelin levels was completely prevented by subdiaphragmatic vagotomy, and significantly 
reduced by a muscarinic antagonist atropine (Williams et al., 2003). Two pharmacological studies 
also suggested that ghrelin secretion was stimulated by cholinergic/muscarinic agonists, while 
inhibited by muscarinic antagonists (Broglio et al., 2004; Hosoda and Kangawa, 2008). Further, it is 
noteworthy that although clozapine is a muscarinic receptor antagonist, norclozapine (an active 
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metabolite of clozapine) is a partial agonist of muscarinic receptors (Davies et al., 2005; Li et al., 
2005). Therefore, the individual variations on the clozapine: norclozapine ratio (Couchman et al., 
2010) explain, at least partly, the variations of findings in studies reporting on ghrelin levels under 
SGA treatments. 
Studies on sympathetic (in particular adrenergic) control of ghrelin production also provide indirect 
support for the view that SGAs can upregulate ghrelin production. One pharmacological study 
showed that ghrelin secretion in rats was stimulated by an α-adrenergic antagonist phentolamine 
and a β-adrenergic agonist isoproterenol, while inhibited by an α-adrenergic agonist phenylephrine 
(Hosoda and Kangawa, 2008), suggesting an inhibitory role of α-adrenergic signalling and a 
facilitatory role of β-adrenergic signalling on ghrelin secretion. Similarly, an earlier study also 
found that intraperitoneal injections of the selective α1-adrenergic receptor antagonist prazosin 
(0.25mg/kg), the α2-adrenergic  receptor antagonist yohimbine (2mg/kg), and the SGA clozapine 
(10mg/kg) significantly increased blood active ghrelin levels in male Sprague-Dawley rats 
(Murashita et al., 2007b). Since most SGAs are antagonists of α1- and α2-adrenergic receptors 
(Nasrallah, 2008), increased ghrelin levels under SGA treatments could be expected. Taken 
together, the balance between cholinergic and adrenergic signals combined with the antagonist 
and/or partial agonist properties of SGAs on the corresponding receptors provides a possible 
explanation for the initial effects of SGAs on ghrelin production. 
3.2 Secondary effects of SGAs on circulating ghrelin levels  
After the appearance of the initial upregulatory effect on ghrelin production, during the short- to 
mid-term of the SGA treatments, results from clinical studies become more inconsistent. One study 
investigated the effect of olanzapine, clozapine, antidepressants with weight gain, other 
antipsychotics, and other antidepressants on circulating ghrelin levels showed that after 8-14 days of 
treatment, there was no significant difference in circulating total ghrelin levels amongst treatment 
groups (Himmerich et al., 2005). Other short- to mid-term studies suggested that circulating total 
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ghrelin levels are decreased compared to the baseline or control after 2-6 weeks of SGA treatments 
(Basoglu et al., 2010; Roerig et al., 2008; Tanaka et al., 2008; Vidarsdottir et al., 2010). These 
findings indicate that after the initial upregulatory effect, ironically, SGAs produced a 
downregulatory effect on the circulating ghrelin levels during the short- to mid-term of the 
treatments in humans, which can cancel out the initial upregulatory effect or even push the levels 
further below the baseline. Interestingly, animal studies also showed a similar trend, with one study 
showing no difference in active ghrelin levels (Albaugh et al., 2006) and another study showing 
decreased total ghrelin levels (Davey et al., 2012) after 2-3 weeks of olanzapine treatments; 
although another 2-week study still shows an upregulatory effect in total ghrelin levels (Weston-
Green et al., 2011). Moreover, our unpublished data also showed that after 2 weeks and 5 weeks of 
treatment, there was no difference in plasma total ghrelin levels between the olanzapine and control 
groups (Zhang et al., unpublished data). Together, these data may suggest a secondary 
downregulatory effect of SGAs on circulating ghrelin levels, which could be due to the increased 
body weight and food intake triggered by the initial SGA treatment. In fact, ghrelin levels are lower 
in obese humans (Tschop et al., 2001), and the SGA-treated patients in the above-mentioned short- 
to mid-term clinical studies had significantly increased body weight (Hosojima et al., 2006; Roerig 
et al., 2008) or BMI (Basoglu et al., 2010), indicating a possible negative feedback mechanism of 
reduced ghrelin levels in response to SGA-induced weight gain. 
3.3 Longer term effects of SGAs on circulating ghrelin levels 
Clinical studies reporting on ghrelin levels after 8-16 weeks of SGA treatments showed that neither 
total (Popovic et al., 2007; Smith et al., 2012; Tanaka et al., 2008) nor active (Tanaka et al., 2008; 
Theisen et al., 2005) ghrelin levels during these treatment periods were significantly different from 
the baseline or control (Table 1), indicating a recovery of ghrelin levels to the baseline after the 
secondary downregulatory effects of SGA-induced weight gain. These findings are in accordance 
with an 8-week animal study which showed that 8 week of olanzapine, haloperidol or vehicle 
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control treatments had no significant difference in circulating ghrelin levels in mice. Furthermore, 
the majority of longer-term studies reporting on ghrelin levels after more than 6 months of SGA 
treatments showed an upregulation effect of SGAs on circulating total (Esen-Danaci et al., 2008; 
Murashita et al., 2007a; Murashita et al., 2005), active (Murashita et al., 2007a; Murashita et al., 
2005; Palik et al., 2005) or desacyl (Perez-Iglesias et al., 2008) ghrelin levels, with the exception of 
two studies (Chen et al., 2011; Kim et al., 2008) (see details in Table 1). Interestingly, both of these 
two studies reported on total ghrelin levels only (Chen et al., 2011; Kim et al., 2008); while the 
three long-term studies reported on active ghrelin levels all indicated that SGAs can increase ghrelin 
levels (Murashita et al., 2007a; Murashita et al., 2005; Palik et al., 2005). Since acyl ghrelin (n-
octanoyl ghrelin) is the biologically active form of ghrelin which binds to the GHS-R1a receptor to 
exert its orexigenic effect (as mentioned earlier in section 2.1), it might be more relevant in the 
context of SGA-induced body weight gain compared to total ghrelin, although SGAs, as suggested 
by another study, also increase desacyl (inactive) ghrelin levels in the long-term (Perez-Iglesias et 
al., 2008). Together, these studies suggested that circulating ghrelin levels return to the levels of, or 
even above baseline after long-term SGA treatments. The exact mechanism for this phenomenon is 
still unknown, although the re-establishment of a new energy balance after the weight gain induced 
by SGAs could be a possible explanation.  
In summary, existing clinical and animal studies suggest that SGAs have an initial upregulatory 
effect on circulating ghrelin levels during the acute- to short-term treatment stage (Fig. 3). This 
effect is possibly due to the direct effect of SGAs on ghrelin production through neuronal 
regulations over the parasympathetic and sympathetic pathways. After the initial upregulation, 
SGA-induced weight gain produced a downregulatory effect on circulating ghrelin levels during 
short- to mid-term treatments (Fig. 3). At this stage of treatments, human or animal subjects treated 
with SGAs have increased body weight and food intake triggered by the initial SGA treatments, 
which could produce a negative feedback control on circulating ghrelin levels, resulting in the 
overall seemingly downregulatory effect. Eventually, a new energy balance is re-established and the 
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negative feedback effects of the increased body weight and food intake on ghrelin levels are 
removed, leading to the recovery of circulating ghrelin levels back to the baseline level or above 
during the longer term of SGA treatments. 
3.4 Other possible explanations for the effect of SGAs on circulating ghrelin levels 
The discrepancies of the results in clinical studies may also be due to differing medication histories 
and possible co-treatments within study subjects (in particular those who had been treated with 
other antipsychotics), different age range and/or gender composition, and different ghrelin 
measurement techniques used in different studies (see Table 1 for details). Further, different 
antipsychotics can have diverse effects on ghrelin secretion. For example, clozapine tend to have no 
effect on ghrelin levels in the short-term (Himmerich et al., 2005; Popovic et al., 2007; Theisen et 
al., 2005), and risperidone tend to increase ghrelin levels in the long-term (Esen-Danaci et al., 2008; 
Murashita et al., 2005; Palik et al., 2005; Perez-Iglesias et al., 2008). Moreover, differing patient 
hormonal states (other than ghrelin) may also affect ghrelin production. For instance, ghrelin 
secretion was reduced by insulin (Kamegai et al., 2004; Shrestha et al., 2009), and increased by 
cholecystokinin (CCK) (Shrestha et al., 2009) and glucagon (Kamegai et al., 2004). Finally, 
differing dietary choices by study subjects could be another confounding factor for ghrelin 
production, since a high-carbohydrate diet produced a more persistent postprandial inhibitory effect 
on ghrelin secretion than the high-fat diet (Monteleone et al., 2003; Sánchez et al., 2004), which 
was presumably due to the different satiating capacities of these diets.  
In the clinic, female has been suggested as a risk factor and predictor for weight gain associated 
with SGAs and other antipsychotics (Gebhardt et al., 2009; Smith, 2010). In fact, the sensitivity of 
female rodents to the weight gain side-effect of SGAs over males is comparable to that in the clinic 
(Weston-Green et al., 2010). However, only one human study has reported on gender differences in 
ghrelin levels under SGA treatments, but this study showed no gender effect (Himmerich et al., 
2005). In contrast, one recent rodent study reported that plasma ghrelin levels were reduced by 
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olanzapine in females but not in males (Davey et al., 2012). Further studies are required to compare 
the gender differences in the effects of SGAs on ghrelin levels. 
3.5 SGAs upregulate GHS-R1a receptor expressions in the hypothalamus 
In addition to the effects on circulating ghrelin levels, SGAs (in particular olanzapine) have also 
been reported to upregulate hypothalamic levels of the GHS-R1a protein and mRNA expression 
(Davey et al., 2012; Zhang et al., 2012). This could be the results of the initial upregulated ghrelin 
(especially active ghrelin) levels under SGA treatments. Growth hormone-releasing hormone 
(GHRH) and growth hormone secretagogue (GHS) have been reported to upregulate GHS-R1a 
mRNA expression in rat pituitaries (Kineman et al., 1999), and ghrelin has been reported to activate 
GHS-R1a in the rat retina (Zaniolo et al., 2011). In addition, ghrelin treatment reversed the down-
regulated GHS-R1a mRNA and protein levels in the rat cerebral cortex on ischemia/reperfusion 
injury (Miao et al., 2007), and intravenous injection of ghrelin upregulated GHS-R1a mRNA at the 
Arc of the hypothalamus in rats (Nogueiras et al., 2004). Therefore, it is conceivable that elevated 
blood ghrelin levels under SGA treatments upregulate hypothalamic GHS-R1a expression. 
As a possible example, it has been recently reported that some of the dopamine D2 receptor is 
colocalized with the GHS-R1a receptor at the hypothalamus, and heterodimers of D2 receptor and 
the GHS-R1a receptor have been found to naturally exist in cells coexpressing these receptors with 
functional interactions (Kern et al., 2012). Since most SGAs are D2 receptor antagonists, it is 
possible that blocking the D2 receptor by these antipsychotics stimulates the expression of the 
GHS-R1a receptor by a compensatory mechanism. In addition, the D2 receptor agonist requires the 
GHS-R1a receptor to conduct the anorexic effect (Kern et al., 2012). Conversely, is it conceivable 
that SGAs, as D2 antagonists, require the integrity of the GHS-R1a receptor to increase food intake. 
In fact, reduced D2 receptor concentration was detected in obese rats as opposed to lean rats 
(Fetissov et al., 2002; Palmiter, 2007). Furthermore, heterodimerization and functional interaction 
between the GHS-R1a receptor and the 5-HT2c receptor has also been identified recently 
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(Schellekens et al., 2013). Since most SGAs, in particular those with high weight gain liabilities are 
5-HT2c antagonists, it is possible that these SGAs may regulate ghrelin signalling via antagonising 
the 5-HT2c receptors, or vice versa. Finally, the heterodimers between the GHS-R1a receptor and 
the melanocortin-3 receptor (MC3R) (Rediger et al., 2011), and between the GHS-R1a receptor and 
the dopamine D1 receptor (Jiang et al., 2006) have been reported. 
3.6 Ghrelin signalling and the rewarding system in SGA-induced weight gain 
Apart from the effects on the hypothalamic energy homeostatic regulation system, ghrelin 
signalling can also contribute to SGA-induced weight gain through the food rewarding system. 
Ghrelin signalling has been suggested to play a key role in food reward behaviour (for review see 
(Schellekens et al., 2012)). Briefly, the GHS-R1a receptor is also expressed in extra-hypothalamic 
areas such as the ventral tegmental area (VTA) and lacterodorsal tegmental area (LDTg) (Guan et 
al., 1997), which are important nodes in the mesolimbic dopaminergic rewarding circuit. Further, 
ghrelin has also been shown to activate the mesolimbic rewarding system as VTA ghrelin injection 
increases food intake in rodents (Naleid et al., 2005), and dopamine release at the nucleus 
accumbens (NAc) can be stimulated by ghrelin (Jerlhag et al., 2006; Jerlhag et al., 2007). 
Interestingly, SGAs, including olanzapine, have been suggested to deteriorate the pre-existing 
hedonic alterations (enhanced anticipation of food reward) in schizophrenia patients (Elman et al., 
2006; Mathews et al., 2012). However, to the best of our knowledge, the role of rewarding system 
through ghrelin signalling in SGA-induced weight gain has not yet been reported. Given the fact 
that the GHS-R1a receptor has been reported to form heterodimers with D1, D2, and 5-HT2c 
receptors (Jiang et al., 2006; Kern et al., 2012; Schellekens et al., 2013), the interactions between 
the ghrelinergic system and the mesolimbic dopaminergic/mesocortical serotoninergic rewarding 
system in SGA-induced weight gain and hyperphagia warrant further study. 
4. Conclusions and clinical implications 
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SGAs have been associated with more serious hyperphagia, adiposity and body weight gain 
compared to the first-generation antipsychotics. Clinical data has indicated ghrelin production and 
signalling is upregulated, at least in a subpopulation of patients under SGA treatments (Esen-Danaci 
et al., 2008; Murashita et al., 2007a; Murashita et al., 2005; Palik et al., 2005; Perez-Iglesias et al., 
2008), which was supported by the majority of acute and chronic animal studies (Murashita et al., 
2007b; van der Zwaal et al., 2012; Weston-Green et al., 2011). Although ghrelin signalling is only 
indirectly related to SGAs, and therefore other mechanisms (for example, antagonism of H1, H3, 5-
HT2a, M3 receptors) cannot be excluded, the majority of data as discussed above indicate that the 
altered ghrelin signalling under SGA treatments can at least partly explain the weight gain side-
effects induced by SGAs. In addition, it has been suggested that ghrelin induces adiposity (Choi et 
al., 2003) and suppresses energy expenditure (Asakawa et al., 2001; Tang-Christensen et al., 2004), 
independent of its effect on body weight gain, which also coincide with the effects of SGAs with 
weight gain liabilities (Albaugh et al., 2011; Evers et al., 2010; Monda et al., 2008; Skrede et al., 
2012; Stefanidis et al., 2009; van der Zwaal et al., 2010). 
Based on existing data, it is conceivable that SGAs upregulate ghrelin production through a 
complex regulation system involving the balance between sympathetic and parasympathetic 
nervous systems. The elevated ghrelin signals are conducted to the hypothalamus, the energy 
homeostasis regulation centre, through neuronal afferent pathways, or to a lesser extent, through 
direct actions at the Arc or DVC by passing through the BBB. The GHS-R1a receptor expression at 
the hypothalamus is also upregulated under SGA treatments (Davey et al., 2012; Zhang et al., 2012), 
possibly through the elevated circulating ghrelin levels.  The elevated ghrelin signals integrated at 
the hypothalamus upregulate the Arc orexigenic neuropeptides AgRP and NPY, possibly through 
the activation of the transcription factors BSX, FOXO1 and pCREB. Innervated NPY/AgRP 
neurons at the Arc can thus inhibit the nearby POMC neurons, further enhancing the hyperphagic 
signals of ghrelin, leading to body weight gain. 
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It has been suggested that SGAs’ weight gain liabilities are associated with their antagonism on H1, 
5-HT2a, 5-HT2c and D2 receptors. While SGAs act on each of these systems independently and 
contribute to the weight gain side-effects, these systems also interact with the ghrelinergic system to 
create a synergistic effect on food intake and body weight gain. Given the fact that the GHS-R1a 
receptor can form heterodimers and have functional interactions with the 5-HT2c and D2 receptors, 
further research is required to untangle the relationships of the effects of SGAs on these systems 
and to elucidate the exact mechanisms of SGA-induced hyperphagia and weight gain. 
Considering the increased ghrelin levels in patients after weight loss, inhibiting ghrelin signalling 
by blocking/antagonising the GHS-R1a receptor may be an attractive strategy to maintain body 
weight loss and to prevent body weight gain under SGA treatments. Furthermore, animal studies 
have revealed that weight reduction by food restriction not only increases circulating ghrelin levels, 
but also the level of the GHS-R1a receptor at the hypothalamus and the sensitivity of GHS-R1a to 
ghrelin receptor agonists. Thus, blocking ghrelin signalling by GHS-R1a antagonists or inverse 
agonists could be a promising strategy to help maintain weight loss in SGA-induced obese patients. 
In fact, [D-Lys-3]GHRP-6, a GHS-R1a antagonist, has been reported to reduce food intake and 
body weight gain in mice (Asakawa et al., 2003) and rats (Beck et al., 2004). Therefore, whether 
GHS-R1a antagonists are effective targets in attenuating hyperphagia and body weight gain in an 
animal model and translating these results into clinical studies warrants further research. Finally, to 
elucidate the role of ghrelin signalling in SGA-induced weight gain, future studies should also 
investigate the effects of SGAs on energy balance regulation in ghrelin signal-deficient models (e.g. 
ghrelin-knockout or GHSR-knockout animals). In conclusion, recognizing the upregulation of 
ghrelin signalling under SGA treatments could lead to novel therapeutic approaches for tackling the 
weight gain side-effects of SGAs. 
  
Table 1. Effect of SGAs on circulating ghrelin levels – Human Studies 
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Figure 1: Schematic illustration of afferent pathways of ghrelin signalling and the hypothalamic orexigenic system.
a. The upregulated ghrelin hormone under SGA treatment binds to the ghrelin receptors located at the GI tract and the vagal
afferents, from where the ghrelin signals are transmitted to the DVC of the brainstem. Alternatively, ghrelin can pass through 
the BBB at the DVC and relay to the hypothalamus, or pass the BBB at the hypothalamus. 
b H th l i l t k l i th i i ff t f h li Gh li ti l t th NPY/A RP t th. ypo a am c neurona  ne wor s re ay ng  e orex gen c e ec  o  g re n.  re n s mu a es  e  g neurons a   e 


























Figure 2: Intracellular signalling pathways of ghrelin signalling in NPY/AgRP neuronal cells of the hypothalamic arcuate nucleus.
The upregulated ghrelin under SGA treatment will activate the ghrelin receptor (GHSR1a) at the NPY/AgRP neuronal cell membrane 
























































adrenergic signals by blocking the α1‐/ α2‐ ARs (2). Removing inhibitory signals increased ghrelin secretion from the stomach (3), 
which stimulated the expression of GHS R1a at the NPY/AgRP neurons in the Arc of the hypothalamus (4) Enhanced ghrelinergic          ‐                     .   
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